Recon: Supreme Court won’t review Oklahoma PBM law; Senate passes megabill after marathon voting session

• Supreme Court declines to review Oklahoma law regulating PBMs (STAT)
• HHS to continue funding cancer prevention, tracking work in states after uncertainty (STAT)
• Vance breaks 50-50 tie as Senate passes GOP megabill after voting around the clock (The Hill)
• House committee subpoenas Pfizer executive in probe of alleged Covid vaccine delay (CNN)
• AstraZeneca CEO wants to move listing to the US (The Times of London)

• European Commission Asks For ‘Open Minds’ On Unified Drug/Device Research Pathway (MedTech Insight)
• EU approves Vertex's next-generation cystic fibrosis drug (Reuters)
• China's Innogen expects to complete weight-loss drug trials next year (Reuters)
• China Enlists Commercial Insurers in Bid to Boost Local Biotechs (Bloomberg)
• Torrent Pharma shells out $1.4B to take over controlling stake in India's JB Pharma from KKR (Fierce Pharma)

• Sage Therapeutics cuts most of its workforce following acquisition (STAT)
• Lessons from Duke’s nuked mega cord blood deal with Cryo-Cell (STAT)
• How Novo Nordisk misread the US market for its weight loss sensation (Reuters)
• Advocates urge J&J to ‘put everything on the table’ for gene therapy despite failed trial (Endpoints)
• Kevin Tang's Concentra snags another buyout, this time for IGM Biosciences (Endpoints)
• Unnatural Products taps argenx's help for ringed molecules, expands internal work into obesity (Endpoints)
• Pfizer ends Phase 2 trial for final Trillium CD47 drug (Endpoints)
• Exclusive: Sama Fertility raises $3.8M to make IVF more accessible (Endpoints)
• How Will Regulatory Filing Winds Blow Globally For Elevidys Following Patient Deaths? (Pink Sheet)
• FDA weighs regulatory action on argenx's Vyvgart Hytrulo amid reports of 'severe worsening' of disease (Fierce Pharma)

• Who benefits from over-the-counter CGMs? (MedTech Dive)
• Carmat files for insolvency amid cash crunch (MedTech Dive)
• New glucose sensors, insulin patch pumps lead ADA’s Scientific Sessions (MedTech Dive)
• Olympus pledges prompt response following FDA import block (MedTech Dive)
• Medtronic’s ‘Strategic Expansion’ Into Remote Monitoring (MedTech Insight)
• Brainlab CEO in internal memo blames geopolitical uncertainties for putting IPO on ice (Reuters)

• Conagra Brands to Remove FD&C Colors from U.S. Frozen Product Portfolio by End-2025 (Food Safety)

• RFK Jr. says he has a team working on changes to the vaccine injury compensation program (STAT)
• UnitedHealth, Sloan Kettering Resolve Contract Dispute (Bloomberg)
• US FDA’s Tough Talk On Talc: Regulating In An Echo Chamber (Pink Sheet)
• Early Support For EMA’s Trial Of US-Style Standards In Non-Clinical Reviews (Pink Sheet)
• SCOTUS ruling paves smooth launch path for Gilead's long-acting PrEP med Yeztugo, analyst says (Fierce Pharma)